Fairmount Funds Management’s Spyre Therapeutics SYRE Stock Holding History

Fairmount Funds Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,018,101	Closed	-$203M	–	13
2026 Q1	$203M	Hold	4,018,101	–	–	14.64%	4
2025 Q4	$132M	Hold	4,018,101	–	–	10.02%	3
2025 Q3	$67.3M	Hold	4,018,101	–	–	6.06%	10
2025 Q2	$60.2M	Hold	4,018,101	–	–	7.79%	5
2025 Q1	$64.8M	Hold	4,018,101	–	–	10.06%	3
2024 Q4	$93.5M	Hold	4,018,101	–	–	9.3%	3
2024 Q3	$118M	Hold	4,018,101	–	–	9.58%	4
2024 Q2	$94.5M	Buy	4,018,101 +3,639,680	+962%	+$123M	10.67%	3
2024 Q1	$14.4M	Hold	378,421	–	–	1.56%	14
2023 Q4	$8.14M	Hold	378,421	–	–	0.86%	16
2023 Q3	$4.64M	Sell	378,421 -1	-0%	-$13	0.56%	20
2023 Q2	$4.26M	Buy	+378,422	New	+$1.79M	0.6%	17

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fairmount Funds Management's SYRE Position: Q2 2026 in Review

Fairmount Funds Management sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 4,018,101 shares — an estimated $203M sold.

Fairmount Funds Management first reported a position in SYRE in Q2 2023 and held it in 12 quarters. The position peaked at $203M in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Fairmount Funds Management reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
Fairmount Funds Management sold 4,018,101 Spyre Therapeutics shares in Q2 2026, an estimated $203M.
Fairmount Funds Management first reported a position in Spyre Therapeutics in Q2 2023 and held it in 12 quarters.
Fairmount Funds Management's Spyre Therapeutics position peaked at $203M in Q1 2026.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.